-
Pharma, Research Group Partner on Meningitis Therapy
26 August 2016. A collaboration between a company developing anti-fungal drugs and research group specializing in fungal infections aims to advance a new type of therapy for cryptococcal meningitis, a life-threatening infection affecting the brain and spinal cord. Financial details of the partnership between Viamet Pharmaceuticals in Research Triangle Park, North Carolina and Mycoses Study Group Education and Research Consortium in Birmingham,…
-
Injected Gel Designed to Deliver Cancer Therapy
26 August 2015. Biomedical engineers at Harvard University devised a hydrogel material that when infused with tumor and immune-system cells can stimulate a therapeutic immune response in lab mice. The team from Harvard’s Wyss Institute, a biomedical engineering research center, published its findings earlier this month in the journal Nature Communications (paid subscription required). The…
-
Alerts in Health Records Cut Delays in Cancer Diagnosis
25 August 2015. Medical researchers found electronic triggers that alert physicians when test results suggest a potential for cancer, reduce delays for patients needing follow-up care. The team led by Hardeep Singh, a professor at Baylor College of Medicine in Houston, published its findings yesterday in Journal of Clinical Oncology (paid subscription required). In addition…
-
All-Purpose Hand-Held Device Checks for Vital Signs
24 August 2015. Biomedical engineers at Johns Hopkins University in Baltimore developed a portable device that quickly returns a person’s vital health indicators in an ambulance, at an outpatient clinic, or even at home. Test results of the device, called MouthLab, led by biomedical engineering and of otolaryngology professor Gene Fridman, appear in the September…
-
Small Business Grant Funds Preclinical Lupus Research
24 August 2015. A grant from National Institute of Allergy and Infectious Diseases is funding preclinical research by a biotechnology company on stem cells as a therapy for a type of lupus. The $225,000 grant from NIAID, part of National Institutes of Health, is made to Ocata Therapeutics Inc. of Marlborough, Massachusetts under the institute’s…
-
Synthetic Biology Company Raises $200 Million in IPO
21 August 2015. Intrexon Corp., a company developing genomic solutions with synthetic biology, raised some $200 million in its initial public stock offering. The Germantown, Maryland enterprise issued 4,878,049 shares of common stock priced at $41.00, and traded on the New York Stock Exchange under the symbol XON. The company’s shares closed today at $45.46,…
-
Antipsychotic Drug Savings Expected as Patents Expire
21 August 2015. Medicaid is expected to save nearly $3 billion by the year 2019 from patents expiring on leading branded antipsychotic drugs, and as generic forms of those drugs replace them. Researchers from University of Maryland medical school in Baltimore made those calculations in a paper published last month in the journal Psychiatric Services…
-
Early Trial Results Targeting Cancer Mutations Promising
20 August 2015. A clinical trial testing the efficacy of a cancer drug to treat multiple types of cancer based on a common genomic mutation, showed a melanoma drug could treat at least a few other cancers. A team from the U.S. and Europe, led by researchers from Memorial Sloan Kettering Cancer Center in New…
-
Biomedical Accelerator Accepts 12 New Research Projects (Updated)
20 August 2015, Updated 21 August 2015 (see below). The Blavatnik Biomedical Accelerator at Harvard University is adding 12 new campus research projects to transform their findings into marketable products and services. The accelerator aims to bridge the gap between academic labs and venture financing, often called the Valley of Death because of the lack…
-
Flatiron, Guardant Partner on Cancer Genomics, Analytics
19 August 2015. Guardant Health, a provider of genomic analysis from liquid biopsies, and Flatiron Health, a provider of electronic records and analytics for cancer patients are collaborating on a cloud-based platform to support research leading to targeted therapies for cancer patients. The companies expect the service to be available in the first half of…